VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F. Stojdl, John C. Bell, Anthony Power et al.|Cancer Cell|2003Cited by 850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virusDavid F. Stojdl, John C. Bell, Brian D. Lichty et al.|Nature Medicine|2000Cited by 816